Amylopectinosis of the fatal epilepsy Lafora disease resists autophagic glycogen catabolism

Jun Wu; Or Kakhlon; Miguel Weil; Alexander Lossos; Berge A. Minassian

doi:10.1038/s44321-024-00063-9

Amylopectinosis of the fatal epilepsy Lafora disease resists autophagic glycogen catabolism

Jun Wu, Or Kakhlon, Miguel Weil, Alexander Lossos, Berge A. Minassian

Research output: Contribution to journal › Letter › peer-review

Abstract

In this Correspondence, B. Minassian and colleagues report that GHF201, an autophagy activator shown to diminish abnormal glycogen aggregates in a mouse model of Adult Polyglucosan Body Disease, fails to reduce such accumulations in a mouse model of Lafora disease. (Figure presented.)

Original language	English (US)
Journal	EMBO Molecular Medicine
DOIs	https://doi.org/10.1038/s44321-024-00063-9
State	Accepted/In press - 2024

ASJC Scopus subject areas

Molecular Medicine

Access to Document

10.1038/s44321-024-00063-9

Cite this

@article{0eb6395267e34df69839d0a2e75c169a,

title = "Amylopectinosis of the fatal epilepsy Lafora disease resists autophagic glycogen catabolism",

abstract = "In this Correspondence, B. Minassian and colleagues report that GHF201, an autophagy activator shown to diminish abnormal glycogen aggregates in a mouse model of Adult Polyglucosan Body Disease, fails to reduce such accumulations in a mouse model of Lafora disease. (Figure presented.)",

author = "Jun Wu and Or Kakhlon and Miguel Weil and Alexander Lossos and Minassian, {Berge A.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

doi = "10.1038/s44321-024-00063-9",

language = "English (US)",

journal = "EMBO Molecular Medicine",

issn = "1757-4676",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Amylopectinosis of the fatal epilepsy Lafora disease resists autophagic glycogen catabolism

AU - Wu, Jun

AU - Kakhlon, Or

AU - Weil, Miguel

AU - Lossos, Alexander

AU - Minassian, Berge A.

PY - 2024

Y1 - 2024

N2 - In this Correspondence, B. Minassian and colleagues report that GHF201, an autophagy activator shown to diminish abnormal glycogen aggregates in a mouse model of Adult Polyglucosan Body Disease, fails to reduce such accumulations in a mouse model of Lafora disease. (Figure presented.)

AB - In this Correspondence, B. Minassian and colleagues report that GHF201, an autophagy activator shown to diminish abnormal glycogen aggregates in a mouse model of Adult Polyglucosan Body Disease, fails to reduce such accumulations in a mouse model of Lafora disease. (Figure presented.)

UR - http://www.scopus.com/inward/record.url?scp=85189205127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85189205127&partnerID=8YFLogxK

U2 - 10.1038/s44321-024-00063-9

DO - 10.1038/s44321-024-00063-9

M3 - Letter

C2 - 38565807

AN - SCOPUS:85189205127

SN - 1757-4676

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

ER -

Amylopectinosis of the fatal epilepsy Lafora disease resists autophagic glycogen catabolism

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this